Gut microflora as a target for energy and metabolic homeostasis

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 10, Issue 6, 2007, Pages 729-734

  Cani, Patrice D ^a   Delzenne, Nathalie M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Energy metabolism; Gut microflora; Lipopolysaccharide; Microbiota; Obesity; Type 2 diabetes

Indexed keywords

COLON; DAILY LIFE ACTIVITY; DIET; ENERGY BALANCE; ENERGY METABOLISM; ENVIRONMENTAL FACTOR; FEEDING BEHAVIOR; HEALTH STATUS; HOMEOSTASIS; HOST PATHOGEN INTERACTION; HUMAN; HUMAN GENOME; INTESTINE FLORA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; REVIEW; SCIENTIST;

BACTERIAL PHYSIOLOGY; DIET; ECOSYSTEM; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; INTESTINES; PROBIOTICS;

MAMMALIA;

EID: 37349018683     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3282efdebb     Document Type: Review

References (47)

1. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444:840-846. This paper outlines the different mechanisms involved in the development of obesity and their relation to type 2 diabetes and insulin resistance.
2. Tappy L. Metabolic consequences of overfeeding in humans. Curr Opin Clin Nutr Metab Care 2004; 7:623-628.
3. Levin BE, Keesey RE. Defense of differing body weight set points in diet-induced obese and resistant rats. Am J Physiol 1998; 274:R412-R419.
4. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 1977; 31:107-133.
5. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444:1027-1031. This paper outlines that the obese microbiome has an increased capacity to harvest energy from the diet.
6. Xu J, Mahowald MA, Ley RE, et al. Evolution of symbiotic bacteria in the distal human intestine. PLoS Biol 2007; 5:e156. This paper illustrates the fact that the adaptation to the gut habitat is a dynamic process that includes the acquisition of genes from other microorganisms. These findings emphasize the importance of including the evolution of 'our' microbial genomes when considering the evolution of humans.
7. Xu J, Gordon JI. Inaugural article: Honor thy symbionts. Proc Natl Acad Sci USA 2003; 100:10452-10459.
8. Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized healthcare. Nat Rev Microbiol 2005; 3:431-438.
9. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006; 124:837-848.
10. Dethlefsen L, Eckburg PB, Bik EM, Relman DA. Assembly of the human intestinal microbiota. Trends Ecol Evol 2006; 21:517-523. This review presents promising tools and strategies that lead to a functional view of single populations within the microbial community in the human colon.
11. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312:1355-1359. This metagenomics analysis defines the gene content and encoded functional attributes of the gut microbiome in healthy humans.
12. Hill JO. Understanding and addressing the epidemic of obesity: an energy balance perspective. Endocr Rev 2006; 27:750-761.
13. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101:15718-15723.
14. Ley RE, Backhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005; 102:11070-11075.
15. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444:1022-1023. This study performed in obese individuals describes the composition of gut microbiota following a fat-restricted or a carbohydrate-restricted low-calorie diet.
16. Bajzer M, Seeley RJ. Physiology: obesity and gut flora. Nature 2006; 444:1009-1010.
17. Cani PD, Neyrinck AM, Maton N, Delzenne NM. Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like Peptide-1. Obes Res 2005; 13:1000-1007.
18. Cani PD, Daubioul CA, Reusens B, et al. Involvement of endogenous glucagon-like peptide-1(7-36) amide on glycaemia-lowering effect of oligofructose in streptozotocin-treated rats. J Endocrinol 2005; 185:457-465.
19. Cani PD, Knauf C, Iglesias MA, et al. Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes 2006; 55:1484-1490.
20. Cani PD, Joly E, Horsmans Y, Delzenne NM. Oligofructose promotes satiety in healthy human: a pilot study. Eur J Clin Nutr 2006; 60:567-572.
21. Keenan MJ, Zhou J, McCutcheon KL, et al. Effects of resistant starch, a nondigestible fermentable fiber, on reducing body fat. Obesity 2006; 14:1523-1534.
22. Kleessen B, Hartmann L, Blaut M. Oligofructose and long-chain inulin: influence on the gut microbial ecology of rats associated with a human faecal flora. Br J Nutr 2001; 86:291-300.
23. Kolida S, Saulnier DM, Gibson GR. Gastrointestinal microflora: probiotics. Adv Appl Microbiol 2006; 59:187-219.
24. Kolida S, Meyer D, Gibson GR. A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans. Eur J Clin Nutr 2007; 31 January [Epub ahead of print]. This intervention study determines the bifidogenic dose of fructooligosaccharides in healthy humans.
25. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007; 104:979-984.
26. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115:1111-1119.
27. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860-867. A dense review collecting data supporting the link between inflammation, obesity, type 2 diabetes and insulin resistance.
28. Neal MD, Leaphart C, Levy R, et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol 2006; 176:3070-3079.
29. Vreugdenhil AC, Rousseau CH, Hartung T, et al. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol 2003; 170:1399-1405.
30. Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-1433.
31. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56:1761-1772.
32. Brun P, Castagliuolo I, Leo VD, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 292:G518-G525. This paper outlines the role of gut microbiota and endotoxemia in the development of nonalcoholic steatohepatitis in an obese mice model.
33. Pappo I, Becovier H, Berry EM, Freund HR. Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat. J Surg Res 1991; 51:106-112.
34. Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292:E740-E747. This paper is the first study performed in humans showing that type 2 diabetes is associated with increased endotoxemia, and that adipose tissue is able to initiate an innate immune response.
35. Macfarlane S, Macfarlane GT, Cummings JH. Review article: prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther 2006; 24:701-714. This is a complete overview of the current knowledge about prebiotics, with comprehensive and illustrative tables and figures.
36. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125:1401-1412.
37. Griffiths EA, Duffy LC, Schanbacher FL, et al. In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration andmucosal immunity in Balb/c mice. Dig Dis Sci 2004; 49:579-589.
38. Wang Z, Xiao G, Yao Y, et al. The role of bifidobacteria in gut barrier function after thermal injury in rats. J Trauma 2006; 61:650-657. This paper relates the role of bifidobacteria in maintaining gut barrier function.
39. Wang ZT, Yao YM, Xiao GX, Sheng ZY. Risk factors of development of gut-derived bacterial translocation in thermally injured rats. World J Gastroenterol 2004; 10:1619-1624.
40. Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improves high-fat diet-induced diabetes through a mechanism associated with endotoxemia. Diabetologia (in press).
41. Archer BJ, Johnson SK, Devereux HM, Baxter AL. Effect of fat replacement by inulin or lupin-kernel fibre on sausage patty acceptability, postmeal perceptions of satiety and food intake in men. Br J Nutr 2004; 91:591-599.
42. Whelan K, Efthymiou L, Judd PA, et al. Appetite during consumption of enteral formula as a sole source of nutrition: the effect of supplementing pea-fibre and fructo-oligosaccharides. Br J Nutr 2006; 96:350-356.
43. Daubioul CA, Horsmans Y, Lambert P, et al. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr 2005; 59:723-726.
44. Flint HJ, Duncan SH, Scott KP, Louis P. Interactions and competition within the microbial community of the human colon: links between diet and health. Environ Microbiol 2007; 9:1101-1111. This review focuses on the response of the bacterial community of the large intestine and its metabolic outputs to dietary change.
45. Louis P, Scott KP, Duncan SH, Flint HJ. Understanding the effects of diet on bacterial metabolism in the large intestine. J Appl Microbiol 2007; 102:1197-1208.
46. Blaut M, Clavel T. Metabolic diversity of the intestinal microbiota: implications for health and disease. J Nutr 2007; 137:751S-755S. This paper situates the role of gut microbiota in the conversion of nutrients and nonnutritive substances which lead to the formation of compounds that may have beneficial or adverse effects on human health.
47. Ordovas JM, Mooser V. Metagenomics: the role of the microbiome in cardiovascular diseases. Curr Opin Lipidol 2006; 17:157-161. An excellent and clear review of the various mechanisms whereby gut microbiota can affect the occurrence of cardiovascular diseases.